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Snml'rlary 
The gene encoding a highly immunogenic mycobacterial heat-shock protein (hsp65) was transfected 
into the murine macrophage tumor cell line J774.  The resulting hsp65-expressing cells 0774- 
hsp65) were no longer able to produce tumors in syngeneic mice. This loss of tumorigenicity 
was not mediated through T cells since the transfected cells did not produce tumors in atbymic 
mice. If mice are :first immunized with the J774-hsp65 cells and then challenged with the parent 
J774 cells,  the mice do not develop tumors, indicating that the presence of the mycobacterial 
hsp65 protein greatly enhances immunological recognition of unique structures expressed by 
the parent tumor cells. This is further confirmed by the demonstration in vitro of T cells derived 
from J774-hsp65-immunized mice that are cytotoxic for the parent J774 cells. The results provide 
the basis for a novel strategy for enhancing the immunological recognition and decreasing the 
tumorigenicity of transformed cells. 
H 
'eat-shock proteins (hsp's) are molecular chaperones, medi- 
￿9 ating the assembly and folding of other proteins (1-5). 
They have been reported to be expressed at abnormal levels 
in tumor cells (6-9),  and in a murine sarcoma model, the 
tumor-specific antigen has been shown to be a hsp (10). They 
are among the most immunogenic molecules known (11-14). 
The cause of this immunodominance is thought to reside 
in their universal distribution and high degree of sequence 
conservation, resulting in continuous priming of the immune 
system. Mycobacterial hsp's have been used as carder mole- 
cules for circumventing the need for adjuvants to greatly en- 
hance immune responses to unrelated antigens (15,  16). 
Although spontaneously arising tumors are usually very 
weakly antigenic, their recognition by cytotoxic T cells and 
elimination in vivo can be greatly enhanced if they are en- 
gineered to express cytokine genes such as IL-2 (17) or IL-4 
(18).  Thus,  such cells must express unique structures that 
can be targets for immunological recognition. In an alterna- 
tive approach to enhance specific immunity to tumor cells, 
we have transfected a highly malignant macrophage tumor 
cell line with the mycobacterial 65-kD hsp-encoding gene 
(hsp65).  We find that not only do hsp65-expressing tumor 
cells lose their tumorigenicity in mice, but immunization of 
mice with the transfected cells induces strong T  cell-medi- 
ated cytotoxic responses against the parent untransfected cells, 
and such mice are protected against challenge with the parent 
cells.  The transfer of cytokine genes for cancer therapy has 
been widely reported, and in some cases has reached the stage 
of clinical trials (19, 20); transfer of the mycobacteria165-kD 
hsp gene to tumor cells represents a novel strategy for an 
immunotherapeutic  or  immunoprophylactic  approach  to 
cancer. 
Materials and Methods 
Cells and Cell Culture.  Psi-CRE, J774G8 0774; reference 21) 
cells and its transfected derivates (J774-vector  and J774-hsp65) were 
maintained in DME with 10% newborn calf serum. Wehi 164 and 
Pu518 cells were maintained in RPMI 1640 with 12% FCS. All 
media contained 100 #g/ml streptomycin, 100 #g/ml penicillin, 
1 mM t-glutamine,  and 10 mM Hepes. 
Transfection ofJ774  cells with the Mycobacterium leprae hsp65 
Gene.  The transfection was carried out as described previously 
(22, 23). Briefly, the M. Ieprae  65-kD hsp gene was cloned into 
the retroviral shuttle vector pZIPNeoSV(x). This was transfected 
by calcium phosphate precipitation into the virus-packaging cell 
line psi-CRE. The helper-free,  replication-defective,  ecotropic retro- 
viruses obtained were used to infect  J774 tumor cells. InfectedJ774- 
hsp65 cells  were selected  by culturing in 0.8 mg/ml neomycin  (G418; 
Sigma Chemical Co., St. Louis, MO). Expression of the 65-kD 
hsp gene was assessed by Northern and Western blotting and by 
FACS  |  analysis (Becton Dickinson & Co., Mountain View, CA) 
of cells after indirect labeling using mAb CIII8, which recognizes 
the M. leprae  65-kD protein, and FITC-labeled sheep anti-mouse 
F(ab')2 antibody  (Boehringer, Mannheim,  Germany). J774 cells 
transfected with vector alone (J774-vector)  were prepared in parallel. 
mAbs and Immunofluorescence. mAbs  against  H-2K  a,  Fcy2 
receptor, LFA-1, and Pgp-1 (CD44) were obtained from PharMingen 
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ford, UK). Anti-p53 mAbs 248 and 421 were provided by D. Lane 
(Dundee University, Dundee, UK) and anti-M, leprae hsp65 mAb 
IIIC8 was obtained from the World Health Organization Mycobac- 
terial Monoclonal Antibody Bank (Dr. T. Shinnick, Atlanta, GA). 
Cells were labeled by standard procedures (22) for 30 min at 4~ 
and analyzed using a FACScan  |  microfluorimeter (Becton Dick- 
inson & Co.). 
Inoculation and  Immunization  of Mice.  6-12-wk-old female 
BALB/c, BALB/c athymic, or CBA mice were obtained from 
breeding colonies at the National Institute for Medical Research. 
For the production of  tumors mice were inoculated  intraperitoneally 
with the stated number of tumor cells taken from subconfluent 
cell cultures. Mice were immunized with J774 hsp65 cells by four 
intraperitoneal injections of 106 ceils given at weekly intervals. 
Assessment of TumorSize.  Since  tumors grew in most abdominal 
organs, resulting in an unseparable aggregation of primary tumor 
and abdominal organs, tumor size was calculated  by weighing the 
primary tumor and abdominal organs of the test mice, and sub- 
tracting the weight of  abdominal  organs  for five  age-matched  normal 
controls. 
Cytotoxicit  7 AssaTs.  Mice  were immunized with four intra- 
peritoneal injections of 106 cells at weekly intervals. On day 28, 
spleens were removed  and single-cell  suspensions  prepared in KPMI 
1640 plus 10% FCS. The cells were incubated for 6 d with J774- 
hsp65 cells 3' irradiated by 30 Gy. B cells  were removed  by panning 
on rabbit anti-mouse  IgG-coated plates. CD4 and CD8  T cell 
subsets were purified  as described  previously  (24). Briefly,  NK, CD4, 
and/or CD8 cells were removed by treatment  of cells (10Vml) 
with 10 #g/ml PK136 (anti-NKl.1; PharMingen) and anti-L3T4 
and/or anti-Lyt-2 (Becton Dickinson & Co.) mAbs at 4~  for 30 
min, followed  by incubation with a 1:10 dilution of  rabbit comple- 
ment at 37~  for 60 min, resulting in CD4 and CD8 populations 
that were >90% pure as judged by FACS  |  analysis. To measure 
cytotoxic activity, varying numbers of CD4 or CD8 effector cells 
were incubated with 2,000 target cells per well labeled with nCr 
in triplicate wells for 6 h at 37~  in a V-bottomed 96-well micro- 
titer plate. 51Cr release was measured in wells containing effector 
T cells and target cells (cp~),  wells containing target cells 
incubated in medium alone (cprch~o~,), and in wells containing 
target cells plus 0.1% Triton X-100 (cpmm,~). Percent cytotox- 
icity was calculated using  the formula:  100x[(cprn~w~=t,~  - 
cpmspon,,~,/(Cpmm,m~ -- cpm,pon~o~)]. Target cells 0774-hsp65, 
J774, Pu518, or Wehi 164) were labeled with 51Cr by incubating 
106 cells with 3.7 MBq of SlCr in 0.5 ml RPMI containing 20% 
FCS for 2 h, then washing three times. 
Results  and  Discussion 
The murine macrophage tumor cell line J774 was trans- 
fected with the M. leprae hsp65-encoding gene as previously 
described  (22,  23).  Expression  of the  bacterial  hsp  was 
confirmed using mAbs  directed to the bacterial hsp  (not 
shown). J774 is a BALB/c-derived cell line; the tumorige- 
nicity of the parent 0774) cell line and the hsp-transfected 
(J774-hsp65) cells was tested in euthymic and athymic BALB/c 
and in CBA mice. Euthymic BALB/c mice that received ei- 
ther the J774 cell line or the J774 cell line transfected with 
vector alone (J774-vector) developed tumors within 3 wk when 
given 106 cells (Table 1 and Fig. 1). These were large, highly 
malignant lymphoreticular neoplasms composed of histio- 
cytic cells with many mitoses and cellular pleomorphisms with 
metastases in the spleen, liver, kidney, mesentery, and lung. 
Table  1.  The Tumorigenicity of Transfected (J774-hsp65) and 
Parent (]774) Reticulum Sarcoma Cells in BALB/c,  BALB/c 
Athymic,  and CBA Mice 
Tumor incidence 
Injected tumor cells  Dose  BALB/c  Athymic  CBA 
J774 
J774 
vector 
J774-hsp65 
10  S  4/5  -  - 
1@  9/10  5/5  0/10 
107  5/5  - 
10  s  3/5 
106  14/15  5/5 
106  0/10  0/10  0/10 
107  1/10  2/10  - 
x  107  0/5  -  - 
Mice were injected  intraperitoneally  with the indicated  number of tumor 
cells resuspended  in 0.5 ml endotoxin-free  PBS. Tumor cells were either 
the parent cell  line (J774), the parent  cell  line  tramfected  with the mycobac- 
terial hsp65 gene (J774-hsp65), or the parent cell line transfected  with 
the vector alone (J774-vector). Tumor incidence  was determined  by au- 
topsy and histological  examination 21 d after injection of cells. 
BALB/c mice that received a similar or greater number of 
J774-hsp65 cells did not develop tumors. This loss of tumorige- 
nicity of  J774-hsp65  cells did not appear to be due to rejec- 
tion by T cells, as a similar loss of tumorigenicity was seen 
in athymic mice, but could involve NK cell or antibody- 
mediated killing. It is unlikely to be due to a chance inser- 
tion of the foreign gene into a gene involved in tumorige- 
nicity since we obtained exactly the same results with two 
independently derived hsp65-transfected J774 cell lines. Nei- 
ther the parent cell line nor the transfected tumor cells pro- 
duced tumors in CBA mice, confirming their inability to grow 
across an MHC barrier. 
In an attempt to identify the underlying mechanism for 
their loss of tumorigenicity,  J774-hsp65 cells were compared 
with the parent cell line for differences in in vitro growth 
rate, expression  of MHC class I and II molecules,  and a va- 
riety of cell markers (including Fc and C3b receptor,  LFA-1, 
CD44,  and p53) thought to play a role in cellular interac- 
tions, tumorigenicity, or metastatic potential, and for expres- 
sion of cytokine genes. There was elevated intracellular ex- 
pression of p53 in the hsp-transfected cells (data not shown). 
Lost tumorigenicity of the transfected cells could result from 
the interaction of the hsp with p53, the protein encoded by 
the p53 tumor suppressor  gene. Mutations in the p53 gene 
resulting in dysfunctional p53 protein are the most frequently 
observed genetic lesions in tumors (25). P53 is a DNA-binding 
protein essential for normal cell cycle control, and hsp chap- 
erones play a crucial  role in its conformation and function 
(26, 27). Thus, the increased efficiency of chaperone activity 
in the hsp-65-transfected cells could result in the proper folding 
and conformation of ineffective p53 protein, thereby correcting 
its loss of tumor suppressor  function. The association  be- 
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Growth of transfected tumor cells in normal (A) and athymic 
(B) BALB/c mice. Tumor cells were either the parent J774 cells ([]), the 
parent cell line transfected with vector alone (J774-vector) (￿9  or the 
parent cell line transfected with the mycobacterial hsp65 gene (J774-hsp65) 
(II). Mice were injected intraperitoneally with 106 cells, and tumor size 
was calculated by weighing the primary tumor and abdominal organs of 
the test mice and subtracting the weight of abdominal organs of five age- 
matched normal controls.  For each cell type, 20 mice were inoculated. 
Hve mice were killed on days 7 and 14, and 10 on day 21. 
tween loss of tumorigenicity and elevated p53 expression is 
currently being investigated. 
We next investigated whether mice that had received the 
transfected J774 cells showed any level of protection against 
developing tumors when challenged with the parent cell line. 
The results (Table 2 and Fig. 2) demonstrate a highly significant 
level of protection; J774 produced tumors in naive mice, but 
not in mice that had previously been immunized with J774- 
hsp65 cells. This was confirmed by autopsy and histological 
examination in which no evidence of tumor cells or autoim- 
mune inflammation could be found. A second group of chal- 
lenged mice were completely healthy 6 mo after challenge, 
and 80% have survived for >12 mo. The protection gener- 
ated by J774-hsp65 cells appeared to be mediated by T cells, 
since immunized athymic mice all developed tumors after sub- 
sequent challenge. 
To investigate the specificity of the protective effect, im- 
munized mice were chaUenged with two other cell lines: 
Pu518, which is an unrelated, spontaneous reticulum sarcoma 
of BALB/c origin, and Wehi 164 cells, derived from a methyl 
cholanthrene-induced BALB/c sarcoma.  The results (Table 
2 and Fig. 2) show significant protection against challenge 
with Pu518, but not with Wehi 164 cells. When mice were 
immunized with irradiated J774 cells they were partially pro- 
tected against subsequent challenge (Table 2). This indicates 
that J774 cells do have tumor-associated antigens that nor- 
mally do not induce an effective immune response; the pres- 
ence of the 65-kD hsp in transfected  cells presumably en- 
hances this response. 
Since protection appeared to be T cell mediated, we inves- 
tigated the relationship between protection in vivo and T 
cell-mediated cytotoxicity in vitro. Nonadherent spleen cells 
from mice immunized with J774-hsp65 cells were cultured 
in vitro with irradiated J774-hsp65 cells for 6 d. Purified popu- 
lations of CD4 or CD8 T cells were tested for cytotoxicity 
using J774, J774-hsp65, Pu518, and Wehi 164 cells as targets 
(Figs. 3 and 4). Both CD4 and CD8 populations were highly 
cytotoxic for J774-hsp65 and for the parent J774 cells; deple- 
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Figure 2.  Growth of rumor cells in normal (.4) and athymic (/3) BALB/c 
mice that had been immunized with J774-hsp65 cells.  Mice were immunized 
with four intraperitoneal injections of 106 J774-hsp65 cells at weekly in- 
tervals, and then challenged on day 28 with tumor cells of differing origin. 
The results show tumor size 21 d after challenge in immunized (I) and 
nonimmunized  control ([]) mice. Tumor size was calculated by weighing 
the primary tumor and abdominal  organs of the challenged mice, and sub- 
tracting the weight of abdominal organs of age-matched normal controls. 
The dotted line represents the mean +  2 SD for the weight of internal 
organs of the control mice. "A positive size is recorded, as the weight 
of internal organs of these mice exceeded those of control mice; however, 
no tumors could be detected in these mice, either  macroscopically or 
histopathologically. 
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100 
BALB/c  BALB/c 
Immunization  Challenge  normal  athymic 
J774-hsp65  J774  0/10  5/5 
None  J774  9/10  5/5 
J774-hsp65  J774-vector  0/15  5/5 
None  J774-vector  10/10  5/5 
J774-hsp65  Pu518  2/10  5/5 
None  Pu518  5/5  4/4 
J774-hsp65  Wehi  164  7/9  5/5 
None  Wehi  164  5/5  4/4 
Irradiated J774-vector  J774  4/9  5/5 
None  J774  8/10  5/5 
Mice, either normal or athymic BALB/c, were immunized with four 
intraperitoneal injections of 106 J774-hsp65  cells or 3' irradiated (30 Gy) 
J774-vector cells, given at weekly intervals. On day 28 the mice were 
challenged intraperitoneally with 106 reticulum sarcoma cells of differ- 
ing origins. Tumor incidence was determined by autopsy and histologi- 
cal examination 21  d after challenge. 
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Table  2.  The Effect of Immunization with Transfected Tumor 
Cells (]774-hsp65) on Subsequent Challenge with Reticulum 
Sarcoma Cells 
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Figure 4.  In vitro cytot~ic activity ofsplenocytes from mice immunized 
with J774-hsp65  cells. Mice were immunized with four intraperitoneal 
injections of 106 J774-hsp65  cells at weekly intervals.  Spleen cells were 
cultured for 6 d with irradiated  J774-hsp65 cells, and purified populations 
of CD4 or CD8 cells were tested for cytotoxicity against J774-hsp65  (I-1), 
J774  (A), PUS18 (0),  and Wehi 164 (O) cells. The results  are shown 
as the mean  _+  SD. 
tion of both CD4 and CD8 cells resulted in elimination of 
cytotoxic activity (Fig. 3), confirming that it was T cell medi- 
ated. CD4 and CD8 cells were also cytotoxic, although to 
a lesser degree, against Pu518, but not against Wehi 164 cells. 
Attempts to generate cytotoxic T  cells from naive mice or 
from mice injected with J774 parent cells by in vitro stimu- 
lation with irradiated J774 cells failed, as insufficient T cells 
were obtained after the 6 d  of in vitro stimulation.  Thus, 
there appears  to be a complete correlation between in vivo 
protection and the generation of cytolytic T cells capable of 
lysing these malignant reticulum sarcoma cells. 
We assume that the highly immunogenic nature of the 
Figure 3.  In vitro cytotoxic activity of splenocytes from mice immunized 
with J774-hsp65  cells. Mice were immunized with four intraperitoneal 
injections of 106 J774-hsp65  cells at weekly intervals.  Spleen cells were 
cultured for 6 d with irradiated  J774-hsp65 cells, and purified populations 
of CD4 ([]) or CD8 (O) cells were tested for cytotoxicity against J774- 
hsp65  and J774  cells. Cells depleted of both CD4 and CD8 cells were 
also included (ll). The results are shown as the mean  _+  SD. 
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ognition of other, tumor-associated antigen(s). The use of 
a highly antigenic molecule such as purified protein deriva- 
tive (PPD)  (which contains the 65-kD hsp) to greatly en- 
hance immune responses  to  associated  antigens  has been 
demonstrated previously (28, 29), and more recently the same 
effect has been achieved with recombinant mycobacterial hsp's 
(15, 16). As with superantigens, a genuine primary recogni- 
tion of hsp65 has been reported. T cells from PPD-negative 
individuals (30), and from umbilical cord blood (31), are stimu- 
lated by the mycobacterial hsp65. In our experiments (data 
not shown),  splenocytes from naive BALB/c mice do not 
proliferate in response to J774 cells, but do so strongly in 
response to J774-hsp65 cells, indicating a substantial change 
in the immunogenic properties of the cells after transfection 
with hsp65.  The finding of crossprotection against an un- 
related reticulum sarcoma, Pu518, suggests the presence of 
shared antigens on the two unrelated sarcomas. Shared tumor- 
associated antigens have been found in human mdanomas 
(32) and murine sarcomas (33).  Endogenous expression of 
the bacterial hsp65  appears to be essential for protection; 
BALB/c mice immunized with four weekly injections of 50 
#g recombinant hsp65  (rhsp65)  all  developed large intra- 
abdominal tumors within 3 wk of challenge with J774 or 
J774-vector cells (data not shown). Similarly, preincubation 
ofJ774 cells with 50 #g/ml rhsp65 for 60 min, or injection 
of 50 #g of PPD as an adjuvant with J774  cells,  failed to 
produce protection (data not shown). 
Our results clearly show that transfection of the tumor 
cells with the bacterial hsp65 results in the induction of im- 
munity against the parent tumor cell line; this immunity is 
reflected in the generation of cytotoxic T cells and protective 
immunity against the parent tumor. There is a great deal 
of current interest in the use of gene transfer, for example, 
of IL-2- or TNF-encoding genes, to increase the immuno- 
logical recognition of cancer cells (19, 20). The rapid prog- 
ress that is being made on in vivo transfection, and the tar- 
geting of transgene expression to  tumor cells  (34),  could 
provide a role for the hsp65  gene in such an approach. 
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